PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803328
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803328
The magnetoencephalography (MEG) market is anticipated to grow from USD 307.9 million in 2024 to USD 470.7 million by 2032, progressing at a CAGR of 5.6% from 2025 to 2032. This growth is largely driven by advancements in MEG technologies, the increasing prevalence of neurological disorders, and the growing demand for non-invasive diagnostic tools. MEG, a highly sensitive technique for measuring the magnetic fields generated by neuronal activity, offers a non-invasive method for diagnosing conditions such as epilepsy, brain tumors, dementia, and other neurological disorders. The market is further supported by the rising aging population and a greater focus on early diagnosis and intervention.
Technological advancements, particularly in sensor miniaturization, portability, and integration with artificial intelligence (AI) and machine learning for data analysis, have made MEG systems more accessible and accurate. These innovations have expanded the scope of MEG applications, particularly in clinical settings, as well as research institutions focused on neuroscience. Furthermore, the increasing preference for non-invasive testing methods and the growing awareness of brain health issues have also contributed to the rising demand for MEG devices.
Key Insights
Technological Advancements: MEG systems based on optically pumped magnetometers (OPMs) are expected to experience the fastest growth due to their lower operating costs, enhanced sensitivity, and portability. Unlike traditional superconducting quantum interference devices (SQUIDs), OPM-based systems do not require supercooling, making them more compact, cost-effective, and adaptable for mobile and wearable applications.
Rising Prevalence of Neurological Disorders: The increasing global burden of neurological disorders such as epilepsy, dementia, and stroke is one of the major growth drivers for the MEG market. According to the World Health Organization, the number of people affected by epilepsy is expected to rise to 78 million by 2030, while dementia cases are anticipated to increase significantly. MEG's ability to detect abnormal brain activity with high spatial and temporal resolution makes it a valuable tool for early diagnosis and treatment planning.
Clinical Applications: The clinical segment dominated the market with a 65% share in 2024, driven by the growing need for precise diagnostics in conditions such as epilepsy, dementia, and schizophrenia. Epilepsy, in particular, is one of the most significant applications of MEG, as it allows for the accurate identification of seizure foci, improving surgical outcomes for patients.
Research Applications: The research segment is expected to grow at the highest CAGR due to the increasing focus on understanding brain functions and disorders. Research institutions are investing in MEG to study brain connectivity, cognitive functions, and the dynamics of neuropsychiatric disorders. The U.S. BRAIN Initiative and the European Human Brain Project are fueling this trend by supporting research that requires non-invasive imaging tools like MEG.
End-User Dynamics: Hospitals remain the largest end-user of MEG systems, accounting for 45% of the market share in 2024. The adoption of MEG in hospitals is driven by the need for advanced diagnostic capabilities in neurology departments. However, the academic and research institutes segment is expected to grow the fastest, as more research institutions are adopting MEG technology for neuroscience studies and clinical trials.
Regional Growth: North America holds the largest market share (40%) in 2024, with the U.S. leading the adoption of next-generation MEG systems. The region's high disposable income, advanced healthcare infrastructure, and significant investments in medical research contribute to the growth of the market. Additionally, the increasing focus on reimbursement policies for MEG in North America is expected to further drive its adoption.
Barriers to Entry and Market Competition: The MEG market is consolidated, with a few key players, such as Compumedics Limited, MEGIN, GE Healthcare, and Philips Healthcare, leading the market. The high cost of developing MEG systems, combined with regulatory approval processes and technological complexity, creates significant barriers for new entrants. However, advancements in sensor technology and the rise of AI-powered MEG systems present opportunities for innovation and market expansion.
Partnerships and Collaborations: Collaboration between academia, industry, and government bodies is crucial for the growth of the MEG market. For instance, MEGIN's partnership with FIND Neuro and the funding from the Indian government for the development of next-gen neuroimaging technologies are expected to advance MEG's clinical and research applications.